Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590394 | 0.90 | SMN1; SMN2 (0.37) | KMT2ASMN1; SMN2 | |
| SCHEMBL11104169 | 0.77 | TNKS (0.33) | — | |
| SCHEMBL11108193 | 0.74 | KDM4E (0.39) | — | |
| SCHEMBL1818645 | 0.72 | NPSR1 (0.40) | KMT2AGAASMN1; SMN2 | |
| SCHEMBL4908625 | 0.72 | KMT2A (0.43) | KMT2AGAASMN1; SMN2 | |
| SCHEMBL13777930 | 0.72 | KMT2A (0.46) | KMT2AGAA | |
| SCHEMBL9879791 | 0.70 | — | — | |
| SCHEMBL9878583 | 0.70 | PDE4B (0.31) | — | |
| SCHEMBL9878630 | 0.70 | PDE4B (0.32) | — | |
| SCHEMBL17962561 | 0.69 | SMN1; SMN2 (0.37) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025092985-A1 | PHOSPHODIESTERASE 4B INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 合肥医工医药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119930644-A | Phosphodiesterase 4B inhibitor and preparation method and application thereof | 合肥医工医药股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-117247394-A | Nitrogen-containing heterocycles as PDE4B inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-03-17 | — | — | US | disclosed |
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-03-17 | — | — | US | disclosed |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-01-30 | — | — | US | disclosed |
| WO-1991018887-A1 | DIAMINOPYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1991-12-12 | — | — | WO | disclosed |
| US-4435566-A | HYPOGLYCEMIA, ANTIHISTAMINE, ANTIDIABETIC ACTIVITY | MARUKO SEIYAKU CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | KMT2A 3411/4885GAA 513/4885SMN1; SMN2 3763/4885 |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | KMT2A 3411/4885GAA 513/4885SMN1; SMN2 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.